NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure
18 May 2025 (14:15 - 14:25)
Organised by: 
Slides
About the speaker
Mass General Brigham, Boston (United States of America)
5 More presentations in this session
Doctor J. Torres Zamudio (Cordoba, ES)
Professor T. Kempf (Hannover, DE)
Doctor M. Fudim (Durham, US)
Professor S. Anker (Berlin, DE)
Access the full session
The Event
Heart Failure 2025
18 May 2025
14:15 CET
You may be interested in
Congress Presentation
Congress Presentation
